STADA Arzneimittel AG and Bio-Thera Solutions have secured a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Gotenfia, a proposed biosimilar to the tumor necrosis factor alpha inhibitor golimumab. The product references Simponi, an originator drug widely prescribed for multiple autoimmune conditions. If approved, Gotenfia would be marketed across the European Union, the United Kingdom, Switzerland, and selected additional countries under an exclusive commercialization agreement between the two companies.
Why this may be the most significant anti-TNF biosimilar since adalimumab
The golimumab biosimilar space has remained notably vacant even as other anti-TNF monoclonal antibodies like adalimumab and infliximab have seen an influx of biosimilar competition in Europe. The CHMP recommendation for Gotenfia breaks that pattern. Unlike adalimumab, which has been subject to multiple biosimilar launches since 2018, golimumab has enjoyed an unusually long exclusivity period with Simponi remaining unchallenged in many European markets.
Industry analysts point to golimumab’s once-monthly subcutaneous dosing and strong prescriber loyalty as key reasons behind the delayed competition. Simponi has been viewed as more convenient than other TNF-alpha inhibitors that require more frequent dosing. This convenience factor, coupled with a lack of viable biosimilar challengers until now, has allowed Johnson & Johnson to retain significant market share in Europe, reportedly nearing €700 million in annual sales. The introduction of Gotenfia could mark a new phase in biosimilar competition, one that targets the final stronghold of first-generation biologic immunotherapies.
How STADA and Bio-Thera are aligning for regional control
The regulatory endorsement of Gotenfia underscores the deepening partnership between STADA Arzneimittel AG and Bio-Thera Solutions. Under their 2024 agreement, Bio-Thera is responsible for the development, manufacturing, and supply of the biosimilar, while STADA handles commercialization within the designated territories. The companies have since expanded their collaboration to include other monoclonal antibodies such as tocilizumab.
STADA is not an unfamiliar name in biosimilars. With a specialty-focused commercial engine, it has already established market access and brand presence in immunology through biosimilars of adalimumab and ustekinumab. The addition of golimumab strengthens its rheumatology and gastroenterology positioning across Europe. STADA’s ability to launch Gotenfia with a once-monthly dosing schedule and pre-filled syringe formats, if confirmed in final labeling, will be critical in ensuring competitive parity with Simponi.
Bio-Thera, meanwhile, is steadily transforming from a China-based developer into a global supplier of biosimilars. Its manufacturing capabilities and regulatory execution have enabled approvals across the United States, Europe, and China for a portfolio that includes ustekinumab, tocilizumab, bevacizumab, and adalimumab biosimilars. Gotenfia adds a key immunology asset to this growing global lineup.
What clinical data reveals about regulatory confidence in biosimilarity
The CHMP recommendation was grounded in the totality-of-evidence standard that defines modern biosimilar assessments. Gotenfia, developed under the code BAT2506, underwent comprehensive analytical, non-clinical, and clinical comparisons with the Simponi reference product.
The data package included an extensive analytical comparison of structural, physicochemical, and functional properties, all of which demonstrated high similarity to the reference biologic. A Phase 1, randomized, double-blind, single-dose study in healthy volunteers assessed pharmacokinetics, safety, and immunogenicity across three arms comparing BAT2506 with EU and US versions of Simponi. These were followed by a multicenter Phase 3 trial in patients with psoriatic arthritis. The latter study evaluated efficacy, pharmacokinetics, safety, and immunogenicity across multiple doses and further confirmed clinical equivalence.
The indication set under review includes rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, and juvenile idiopathic arthritis for patients two years and older. The breadth of approved indications will significantly influence physician confidence and formulary inclusion if marketing authorization is granted by the European Commission.
What this enables for health systems and payers under biosimilar policy
From a policy perspective, the Gotenfia opinion offers a clear opportunity for European healthcare systems to expand cost-effective access to one of the few remaining originator TNF inhibitors. Several European countries, particularly in Scandinavia and Central Europe, have aggressive biosimilar adoption policies in place. These range from tender-based procurement systems to automatic substitution frameworks and pharmacy-level incentives.
However, golimumab has remained a blind spot in biosimilar strategies largely due to the absence of viable alternatives. With Gotenfia poised for authorization, national payers may now look to include it in competitive tenders and push for broader switching protocols. The expected use of pre-filled syringe formats at 50 mg/0.5 mL and 100 mg/mL aligns with current clinical practice and should minimize disruption at the prescriber and patient level.
Reimbursement discussions will be shaped not only by pricing but also by confidence in manufacturing reliability and post-marketing pharmacovigilance. Bio-Thera’s track record in regulatory compliance and STADA’s experience in navigating Europe’s fragmented pricing and tendering regimes may prove decisive in achieving fast access across priority markets.
What risks could challenge adoption despite regulatory approval
Even with a likely greenlight from the European Commission, Gotenfia’s commercial trajectory faces non-trivial headwinds. One major concern is prescriber inertia. Many clinicians remain cautious about switching patients who are stable on Simponi, particularly in conditions like rheumatoid arthritis or ulcerative colitis where treatment disruption could lead to flare-ups or complications.
Moreover, golimumab’s once-monthly dosing and familiarity are key advantages that STADA and Bio-Thera must replicate with precision. If there are differences in injection device usability or patient support programs, uptake may be slow despite the regulatory nod.
Manufacturing scale-up is another factor to monitor. Bio-Thera’s supply agreement involves distribution across 27 European Union member states, along with the United Kingdom, Switzerland, Norway, Iceland, and Liechtenstein. Coordinating product flow, managing cold chain logistics, and ensuring lot-to-lot consistency under real-world conditions will all be under close regulatory and payer scrutiny.
Finally, market saturation remains a long-term risk. With adalimumab and infliximab biosimilars already crowding immunology formularies, adding yet another anti-TNF agent may lead some payers to delay inclusion, especially in cost-sensitive markets. STADA’s task will be to position Gotenfia not merely as a low-cost option but as a therapeutically interchangeable and equally convenient alternative.
What this tells us about Bio-Thera’s broader biosimilar ambitions
The Gotenfia milestone is emblematic of Bio-Thera’s evolving role in the global biosimilars race. With five biosimilars already approved across key markets and a pipeline of over 20 candidates, the Guangzhou-based biopharmaceutical company is actively pursuing a model that spans discovery, development, and international commercialization.
Notably, Bio-Thera’s emphasis on next-generation antibody discovery and engineering points to ambitions beyond biosimilars. While the current focus is on immunology and oncology biosimilars, the company is increasingly venturing into antibody-drug conjugates and immuno-oncology agents. Its strategy aligns with a post–PD-1 therapeutic era where treatment precision and targeting capabilities will define commercial success.
Industry analysts suggest that if Gotenfia achieves even moderate market share in Europe, it could unlock new alliance opportunities for Bio-Thera across Latin America, Southeast Asia, and the Middle East. In parallel, STADA could leverage this success to further entrench itself as a specialty biosimilar partner of choice for other developers seeking access to the European market.
Final outlook: A potentially game-changing entry in a cautious but ready market
The positive CHMP opinion for Gotenfia may not immediately rewrite the biosimilar playbook, but it signals the final frontier of anti-TNF competition in Europe is now open. If the European Commission grants approval and STADA executes a coordinated launch, Gotenfia has the potential to reset price expectations, offer prescribers a fully equivalent alternative to Simponi, and expand access for patients with difficult-to-treat autoimmune diseases.
Yet the road ahead is contingent on real-world confidence, not just regulatory equivalence. Success will depend on how seamlessly Gotenfia can slot into current treatment paradigms without triggering prescriber resistance or payer fatigue. For now, Gotenfia stands as a litmus test for whether convenience-driven biologics can be successfully challenged in Europe’s most conservative therapeutic classes.
Can Gotenfia finally unlock biosimilar competition for Simponi in Europe? added by Srinath B on
View all posts by Srinath B →